BiotechTube
IMMvention Therapeutix

IMMvention Therapeutix

Cambridge, United States· Est.
immventionthera.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

IMMvention Therapeutix is a private, preclinical-stage biotech developing small molecule immunotherapies for autoimmune and inflammatory conditions. Operating from the biotech hub of Cambridge, MA, the company is in the early stages of building its pipeline and technology platform. As a pre-revenue entity, its success hinges on advancing its research into clinical development and securing strategic partnerships or funding to validate its approach.

Autoimmune DiseasesInflammatory Diseases

Technology Platform

Small molecule drug discovery platform focused on novel immunomodulatory targets for autoimmune and inflammatory conditions.

Funding History

2
Total raised:$25M
Series A$20M
Seed$5M

Opportunities

The large and growing global market for autoimmune therapies presents a significant opportunity, especially for oral small molecules that could improve patient convenience and access.
Success in one indication could enable rapid expansion into other related inflammatory diseases, creating a broad pipeline.

Risk Factors

High preclinical attrition risk where lead compounds may fail due to efficacy or safety issues.
The company faces substantial financing risk as a private, pre-revenue entity requiring continuous capital to fund R&D.
Intense competition from large, well-resourced pharmaceutical companies in the immunology space.

Competitive Landscape

The competitive landscape is crowded with major pharmaceutical companies (e.g., AbbVie, Johnson & Johnson, Pfizer) and numerous biotechs developing both biologic and small molecule therapies for autoimmune diseases. Differentiation will require demonstrating superior efficacy, safety, or convenience in areas of high unmet need.

More companies in Small Molecule Drugs →More companies in United States →